Tired of ads? Enjoy an ad-free experience by signing up.
👩‍🍳 How we use AI at Tech in Asia, thoughtfully and responsibly.
🧔‍♂️ A friendly human may check it before it goes live. More news here

Former X CEO appointed to lead US healthtech startup eMed

Linda Yaccarino, former CEO of X and longtime NBCUniversal ad executive, has been appointed CEO of eMed, a US-based health tech startup.

eMed initially developed a digital platform for at-home COVID-19 rapid tests and is now focusing on technology for patients using GLP-1 drugs, including those used for weight management and type II diabetes.

Yaccarino led X for two years before stepping down and does not have prior experience in health technology.

eMed recruited Yaccarino for her experience with partnerships and her profile in the tech industry.

GLP-1 drugs, such as Ozempic, have seen rising use and interest for both diabetes care and weight management applications.

🔗 Source: TechCrunch


🧠 Food for thought

1️⃣ Media executives increasingly cross industry boundaries for CEO roles

Yaccarino’s transition from traditional media to healthcare represents a broader trend of proven executives applying their operational skills across different sectors.

At NBCUniversal, she managed over $10 billion in annual revenue and led a team of 1,500 professionals, demonstrating her ability to handle large-scale business operations 1.

Her move from overseeing advertising portfolios to running a social media platform and now a healthcare startup shows how companies increasingly value leadership experience over industry-specific expertise.

This trend reflects how fundamental business skills, such as partnership negotiations, revenue management, and team leadership, often translate across industries, especially in technology-driven sectors.

Her success in transforming NBCUniversal’s advertising business through strategies like the “One Portfolio” approach suggests she brings a track record of navigating industry transitions 1.

2️⃣ Healthcare startups chase massive GLP-1 market opportunity

eMed’s pivot from COVID-19 testing to GLP-1 services reflects how healthcare startups are repositioning to capture the enormous growth in weight management drugs.

The global GLP-1 therapy market is projected to reach $100 billion by 2030, creating significant opportunities for companies building supporting technology platforms 2.

Stay ahead in Asia’s tech landscape

You've reached your 2 free content limit for the month. Sign up for free to read the full story.

🏄 For casual readers / 👶 Free

Basic

US$0

Free forever

Get instant access to this article and more every month

0 premium content

Unlimited news briefs

5

5 articles

Ad-free reading experience

Just US$0 per day

⌛Sign up in 20s. No payment details needed.

📖 For learners / 👍 Starter

Lite

US$4.92/month

Billed annually at US$59/year

Get instant access to this article and more every month

4

4 premium content

Unlimited news briefs & articles

Ad-free reading experience

Just US$0.17 per day

Cancel anytime

Our subscriber community includes professionals from these companies:

Stay updated on the go with our mobile app.

Get latest insights with smoother, more personalized experience through TIA mobile app.